Chapter 51 Canine Hyperadrenocorticism Therapy

  1. Barker E et al: A comparison of the survival times of dogs treated for hyperadrenocorticism with trilostane or mitotane, J Vet Intern Med 19:810, 2005. PUBMED Abstract
  2. Bell R et al: Effects of once daily trilostane administration on cortisol concentrations and ACTH responsiveness in hyperadrenocorticoid dogs, Vet Rec 159:277, 2006. PUBMED Abstract
  3. Burkhardt WA et al: Adrenocorticotropic hormone, but not trilostane, causes severe adrenal hemorrhage, vacuolization, and apoptosis in rats, Domest Anim Endocrinol 40:155, 2011. PUBMED Abstract
  4. Feldman EC: Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism, J Am Vet Med Assoc 238:1441, 2011. PUBMED Abstract
  5. Helm JR et al: A comparison of factors that influence survival in dogs treated with mitotane or trilostane with adrenal-dependent hyperadrenocorticism, J Vet Intern Med 25:251, 2011. PUBMED Abstract
  6. Kintzer PP, Peterson ME: Mitotane (o,p′-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism, J Vet Intern Med 5:182, 1991. PUBMED Abstract
  7. Neiger R et al: Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism, Vet Rec 150:799, 2002. PUBMED Abstract
  8. Ramsey I: Trilostane: a review, Vet Clin North Am Small Anim Pract 40:269, 2010. PUBMED Abstract
  9. Reusch CE et al: Histological evaluation of the adrenal glands of seven dogs with hyperadrenocorticism treated with trilostane, Vet Rec 160:219, 2007. PUBMED Abstract
  10. Ruckstuhl NS, Nett CS, Reusch CE: Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane, Am J Vet Res 63:506, 2002. PUBMED Abstract